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Mutations in genes encoding ion channels, transporters, exchangers, and 
pumps in human tissues have been increasingly reported to cause hypokalemia. 
Assessment of history and blood pressure as well as the K
+ excretion rate and 
blood acid-base status can help differentiate between acquired and inherited 
causes of hypokalemia. Familial periodic paralysis, Andersen’s syndrome, 
congenital chloride-losing diarrhea, and cystic fibrosis are genetic causes 
of hypokalemia with low urine K
+ excretion. With respect to a high rate of K
+ 
excretion associated with faster Na
+ disorders (mineralocorticoid excess states), 
glucoricoid-remediable aldosteronism and congenital adrenal hyperplasia due to 
either 11β-hydroxylase and 17α-hydroxylase deficiencies in the adrenal gland, 
and Liddle’s syndrome and apparent mineralocorticoid excess in the kidney 
form the genetic causes. Among slow Cl¯ disorders (normal blood pressure, 
low extracellular fluid volume), Bartter’s and Gitelman’s syndrome are most 
common with hypochloremic metabolic alkalosis. Renal tubular acidosis caused 
by mutations in the basolateral Na
+/HCO3¯ cotransporter (NBC1) in the proximal 
tubules, apical H
+-ATPase pump, and basolateral Cl¯/HCO3¯ exchanger (anion 
exchanger 1, AE1) in the distal tubules and carbonic anhydroase II in both are 
genetic causes with hyperchloremic metabolic acidosis. Further work on genetic 
causes of hypokalemia will not only provide a much better understanding of 
the underlying mechanisms, but also set the stage for development of novel 
therapies in the future. 
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Introdution
Potassium (K
+), a major intracellular cation, is critically 
important in maintaining the osmotic equilibrium of the 
cell and electrical gradient across the cell membrane. Most 
of the cellular K
+ in the body resides in the intracellular 
fluid (ICF) (~50 mEq/kg, 98%), largely in the skeletal 
muscles (3,000 mEq), red blood cells (300 mEq), and 
liver (200 mEq). In contrast, the total K
+ content in 
the extracellular fluid (ECF) is very low (<1 mEq/kg, 
approximately 2%) and similar to the daily dietary intake 
and renal excretion of K
+. Plasma K
+ concentration is a 
function of total body K
+ and the distribution between 
intracellular and extracellular stores. Hypokalemia, 
defined as plasma K
+<3.5 mEq/L, is the most common 
electrolyte abnormality encountered in clinical practice 
and usually arises from redistribution of K
+ from ECF 
to ICF stores and/or total body K
+ depletion. The most 
significant effects of hypokalemia are cardiovascular, 
neuromuscular, renal, and metabolic, thus associated 
with higher morbidity and mortality
1). Prompt diagnosis 
with appropriate management of hypokalemia avoids 
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unnecessary testing and potential dire complications. The 
treatment of hypokalemia involves weighing the degree 
and timing of hypokalemia with clinical manifestations, 
underlying causes, associated conditions, and risks during 
therapy. 
With the unprecedented progress in molecular and 
genetic analysis, many previously confusing phenotypic 
features of the inherited disorders can now be understood
2). 
Of note, although hypokalemia in these genetic disorders 
may be the foremost finding, one should understand 
that hypokalemia per se is not a specific disease but an 
associated finding in a large number of different diseases
3). 
An accurate diagnosis will help determine the molecular 
defect if the basis for hypokalemia is a genetic disorder. In 
this paper, our approach to hypokalemia is introduced and 
the genetic causes of hypokalemia are discussed to provide 
some insights in the field. 
K
+ homeostasis
K
+ concentration in the ICF is close to 35-fold greater 
than in the ECF and daily K
+ intake is approximately 
equal to the amount of K
+ in the ECF. Maintaining 
normal serum K
+ concentration in the ECF requires tight 
regulation of the distribution of K
+ between the ICF and 
ECF (internal K
+ balance) and renal K
+ excretion (external 
balance)
4). Derangements in either the internal balance (e.g. 
K
+ shift) or external balance (e.g. K
+ wasting) can result in 
hypokalemia. 
1. Regulation of K
+ between ICF and ECF 
1) Driving force
The force driving K
+ shift into cells is the more negative 
voltage in cells. This is created by the Na
+,K
+-ATPase . 
Na
+,K
+-ATPase extrudes three sodium ions (Na
+) for every 
two K
+ ions that enter cells, thus producing a net export of 
positively charged ions. The main hormones that increase 
the activity of Na
+,K
+-ATPase include β2-adrenergic 
agonists, insulin, and thyroid hormone
5) (Fig. 1). Increases 
in the concentration of Na
+ inside cells can also activate the 
Na
+,K
+-ATPase. Insulin stimulates a membrane Na
+/H
+ 
exchanger (NHE), thus helping to prevent hyperkalemia 
when K
+ is ingested in carbohydrate-rich food. Metabolic 
alkalosis also affects the NHE and causes K
+ shift into 
cells. 
2) K
+ channels
K
+ channels are a diverse and ubiquitous family of 
Fig. 1. Regulation of K
+ redistribution in cells and K
+ secretion in the 
cortical collecting duct (CCD). The circle depicts the cell membrane 
(upper panel). Na
+,K
+-ATPase, Na
+/H
+ exchanger (NHE), and K
+ channels 
are three major elements controlling K
+ shift. Na
+,K
+-ATPase is activated 
by β2-adrenergics, insulin and thyroid hormone. NHE, which causes the 
electroneutral entry of Na+ into cells and thus the net exit of positive 
voltage via the Na
+,K
+-ATPase, is also activated by insulin. K
+ channels 
which permit K
+ exit is responsible for generating the majority of the 
resting membrane potential and blocked by barium. The barrel shaped 
structures represent the terminal CCD (lower panel). The reabsorption 
of Na
+ faster than Cl¯ (right) or Cl¯ slower than Na
+ (left) in the CCD 
creates the lumen negative voltage that drives the net secretion of K
+. 
Fast Na
+ disorders cause extracellular fluid (ECF) volume expansion and 
high blood pressure, whereas, slow Cl¯ disorders lead to diminished 
ECF volume and low to normal blood pressure. ENaC, epithelial Na
+ 
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membrane-spanning proteins that selectively conduct K
+ 
ions across the cell membrane along its electrochemical 
gradient in both excitable and non-excitable cells
6). 
There are several different types of K
+ channels. These 
K
+ channels share the common features of a water-filled 
permeation pore allowing K
+ ions to flow across the 
cell membrane, a selectivity filter that specifies K
+ as the 
permeant ion species, and a gating mechanism that serves 
to switch between open and closed channel conformations. 
Because K
+ ions do not reach diffusion equilibrium, 
control of the open-probability of K
+ channel regulates 
the transmembrane voltage. K
+ channels are inhibited by 
barium and other drugs
6). Closure or opening may not 
only alter the membrane potential, but also acutely affect 
the plasma K
+ concentration.
2. Renal handling of K
+ 
Most of the filtered K
+ is reabsorbed by the proximal 
tubule and the loop of Henle. The final amount of K
+ 
excreted in the urine is primarily controlled by the late 
distal convoluted tubule (DCT), the connecting tubule, and 
the cortical collecting duct (CCD)
7). Two factors influence 
the rate of K
+ excretion: the flow rate in the terminal CCD 
and the net secretion of K
+ by principal cells in the CCD 
which raise the luminal concentration of K
+ ([K
+]CCD) 
(Fig. 1). There is an interplay between the magnitudes of 
the flow rate in the CCD and the [K
+]CCD which permits 
the kidney to excrete all the K
+ that is ingested in a steady 
state
8).
1) The flow rate in the CCD
The flow rate in the CCD is directly proportional to the 
rate of excretion of osmoles and can be expressed as the 
urine osmole excretion rate divided by plasma osmolality 
(unrine osmolality × volume/plasma oslmolality) because 
urine osmolality in the terminal CCD is equal to the 
plasma osmolality when anti-diuretic hormone (ADH) 
is present
8). While the rate of flow in the CCD is high 
during a water diuresis, the rate of K
+ excretion need not 
be elevated because ADH must be present to have high 
rates of K
+ secretion. The flow rate in the CCD can also be 
indirectly represented by urine osmolality/creatinine.  
2) [K
+]CCD
K
+ secretion in the CCD depends on the K
+ channel 
conductance of the apical membrane (primarily by 
renal outer medullary K
+ Channel, ROMK) driven by 
the electrogenic reabsorption of Na
+ (a lumen-negative 
transepithelial voltage) via epithelial Na
+ channels (ENaC)
9). 
Blood aldosterone and luminal bicarbonate (HCO3¯) are 
two major factors enhancing K
+ secretion in the CCD
10). 
Aldosterone action leads to an increase in the activity of 
the ENaC and an alkaline luminal pH appears to exert a 
decrease in the apparent permeability of chloride (Cl¯) and/
or an increase in open probability of ROMK. There are 
two ways to generate more negativity in the lumen of the 
CCD and thus drive K
+ secretion. When Na
+ is reabsorbed 
faster than Cl¯ (fast Na
+ disorders) or Cl¯ is reabsorbed 
slower than Na
+ (slow Cl¯ disorders) (Fig. 1), the lumen of 
the CCD becomes more negatively charged (electrogenic) 
and drives K
+ secretion via the ROMK channel. The [K
+] in 
the CCD can be estimated by calculating the transtubular 
K
+ gradient [TTKG=(urine/plasma [K
+])/(urine/plasma 
osmolality)]. A TTKG greater than 3 in the presence of 
hypokalemia indicates fast Na
+ or slow Cl¯ disorders
11). 
Aproach to the genetic causes of hypokalemia
Several acquired extrarenal and renal disorders can 
have the same findings of hypokalemia as genetic causes. 
An understanding of the genetic causes of hypokalemia 
will help determine the molecular defect and avoid 
inappropriate and cumbersome genetic testing. A 
detailed history and measurement of blood pressure 
(BP), K
+ excretion rate, and blood acid-base status can 
help discriminate between the diverse acquired and 
genetic causes of hypokalemia. Historical clues such as 
prior hypokalemia, associated organ abnormalities in 
family members, use of drugs affecting hypokalemia— 
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and nephrolithiasis or nephrocalcinosis must be carefully 
obtained
1). The finding of concomitant hypertension 
and hypokalemia without the use of diuretics suggest the 
presence of a mineralocorticoid excess state (MES). A 
major branch point in hypokalemic pathophysiology is the 
renal K
+ excretion response during hypokalemia. The 24-
hour urine and/or spot urine have been used to assess renal 
K
+ excretion rate. We prefer a spot (timed) urine collection 
prior to therapy as a fast and practical alternative. Four 
spot urine indices of renal response to hypokalemia have 
been used: fractional excretion of K
+, TTKG, urine K
+/
creatinine ratio and urine osmolality/creatinine
1, 12). A 24-
hour urine, if collected properly, can provide additional 
information such as how much K
+ is needed to replace 
the K
+ deficit and the state of K
+ balance from calculation 
of K
+ input and output. Because K
+ deficits usually 
accompany HCO3¯ or Cl¯ loss regardless of the route of 
K
+ loss (gastrointestinal, sweat and renal), either metabolic 
acidosis or alkalosis is common
13). In contrast, conditions 
of intracellular shift usually exhibit relatively normal acid-
base balance. Accordingly, the simultaneous assessment of 
blood acid-base state is also very crucial in patients with 
hypokalemia. Therefore, the etiology of hypokalemia can 
simply be divided into two groups: those with a low K
+ 
excretion rate and those with a high K
+ excretion rate. 
1. Disorders with a low urine K
+ excretion rate 
Disorders in the gastrointestinal tract, excessive sweating 
and conditions with increased shift of extracellular K
+ 
into cells can lead to a low urine K
+ excretion. Generally, 
an increased shift of extracellular K
+ into cells can occur 
acutely in a number of highly stressful conditions associated 
with increased catecholamines or hyperinsulinemia via the 
activation of membrane Na
+,K
+-ATPase or NHE activity. 
Barium intoxication and chloroquine overdose cause 
hypokalemia via the direct closure of cellular membrane 
K
+ channels. One should separate the disorders with 
hypokalemic periodic paralysis (HPP) due to acute shift 
of K
+ into cells from non-HPP, where there is a large total 
body deficit of K
+14). Within the HPP subgroups, the most 
common are thyrotoxic periodic paralysis (TPP) and 
sporadic or idiopathic periodic paralysis (SPP) in Asia and 
familial periodic paralysis (FPP) in Western countries
15). 
1) Genetic hypokalemia due to increased K
+ shift 
(1) Familial hypokalemia periodic paralysis (FPP)
It is an autosomal dominant disorder, which is accom-
panied by muscle weakness or paralysis and occurs more 
frequently in males, with incomplete penetrance and later 
onset observed in affected females
16). Some cases may 
present as sporadic because of the incomplete penetrance 
of the disease, mostly in women. Attacks can be induced 
by rest after exercise, carbohydrate-rich meals, exposure 
to cold, or the administration of glucose or insulin or 
glucocorticoid. Acetazolamide, a carbonic anhydrase 
inhibitor, can reduce the frequency of attacks in FPP with 
unclear mechanisms. The molecular lesions affect ion 
channel genes encoding the dihydropyridine-sensitive 
voltage-gated Ca
2+ channel α1-subunit (CACNA1S) 
(FPP type I) and tetrodotoxin-sensitive voltage-gated 
Na
+ channel α-subunit (SCN4A) (FPP type II) of skeletal 
muscle
17). The Na
+ channel α-subunit shares primary and 
secondary structure with the Ca
2+ channel α-subunit 
including segments spanning the membrane (S1-S6). The 
S4 segment contains a high density of positively charged 
amino acids, with every third one being lysine or arginine, 
and acts as the voltage sensor in voltage-dependent channel 
activation. To date, five point mutations affecting arginine 
substitutions in segment S4 of domains II, III and IV 
(R528G/H, R900S, R1239G/H) of CACNA1S and eleven 
point mutations in segment S4 of domains I, II and III of 
SCN4A (R222W, R669H, R672G,/H/C/S, R675G/Q/
W, R1132Q, R1135H) have been found in patients with 
FPP
18). Why mutations in segment S4 of CACNA1S and 
SCN4A cause episodic hypokalemia remains unclear. 
(2) Andersen-Tawil syndrome
It is an autosmal-dominant channelopathy resulting 
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hypokalemia, but can be normo- or hyperkalemia), cardiac 
arrhythmia (ventricular arrhythmias and QT prolongation) 
and distinctive physical features
19). Mutations in the gene 
(KCNJ2) encoding a pore-forming subunit of the inward 
rectifier K
+ channel protein, Kir2.1, which is expressed 
in skeletal muscles and heart, lead to this syndrome
19). 
The majority of patients with this syndrome have 
missense mutations that inhibit channel function through 
a dominant negative effect. Like FPP, some cases may 
present as sporadic because of the incomplete penetrance 
of the disease or have de novo mutation. Furthermore, a 
wide range of phenotypic severity exists, which can make 
the correct diagnosis difficult. In contrast to FPP, where 
cardiac arrhythmias provoked by severe hypokalemia 
during attacks normalize upon recovery, persistent 
electrocardiogram abnormalities between attacks is likely 
in this syndrome
20).   
2) Genetic hypokalemia where the defect is in the intes  tinal 
tract
Congenital chloride-losing diarrhea (CLD) is a rare 
autosomal recessive disorder characterized by watery 
diarrhea, hypokalemia and hypochloremic metabolic 
alkalosis with high fecal content of Cl¯ (>90 mEq/L)
21). It 
is caused by an inactivating mutation in the downregulated 
in adenoma (DRA) gene encoding a Cl¯/OH¯ (HCO3¯) 
exchanger expressed in the apical membranes of the colon 
and ileum with functional similarities with the anion 
exchange proteins
22) Like acquired intestinal inflammation 
with reduced DRA expression, mutated DRA causes 
the reabsorption of Cl¯ and secretion of HCO3¯ to fall. 
Proton-pump inhibition of gastric chloride secretion is 
helpful in diminishing the delivery of Cl¯ to the colon 
and in lessening the degree of hypokalemia and metabolic 
alkalosis in CLD.
3) Genetic hypokalemia where the defect is in exocrine 
glands
Cystic fibrosis (CF) is an exocrine disease affecting 
multiple organ systems. The defect in the cystic fibrosis 
transmembrane regulator (CFTR), acting primarily as a 
Cl¯ channel, is associated with CF
23). Hypokalemia is not 
uncommon in patients with CF, especially in tropical or 
subtropical areas. Defective chloride reabsorption by the 
dysfunctional CFTR in the sweat ducts of CF patients is 
responsible for excessive Cl¯ and Na
+ loss in sweat. ECF 
volume depletion with secondary hyperaldosteronism not 
only causes Na
+ reabsorption and K
+ secretion in the CCD, 
but may also augment K
+ secretion in sweat ducts and 
thereby contribute to the hypokalemia. 
2. Disorders with a high urine K
+ excretion rate 
Hypokalemia due to renal K
+ wasting is chronic and 
usually related to disorders with either increased flow rate 
to the CCD or increased K
+ in the CCD (fast Na
+ or slow 
Cl¯). 
1) Increased urine flow rate to CCD 
Flow rate to the CCD is enhanced when osmole excre-
tion rate is increased. Increased osmole excretion rate can 
be caused by increased excretion of electrolytes (diuretics 
or tubular defects) or non-electrolytes (mannitol, glucose, 
urea).   
2) Increased [K
+] in the CCD
(1) Fast Na
+ disorders
Because Na
+ reabsorption in the CCD is augmented, 
ECF volume is usually expanded and thus BP is high, 
as in states of mineralocorticoid excess
1). In this setting, 
measurement of plasma renin activity, aldosterone and 
cortisol concentration help to narrow the differential 
diagnosis of fast Na
+ disorders (Fig. 2). Plasma renin 
activity and aldosterone levels are high in patients with 
renin-secreting tumor, renal vascular stenosis, malignant 
hypertension, and pheochromocytoma. High plasma 
aldosterone levels but low plasma renin activity indicates 
primary hyperaldosteronism which can be caused by 
bilateral adrenal hyperplasia, adrenal adenoma/carcinoma, 
and glucocorticoid-remediable aldosteronism (GRA). In Electrolyte Blood Press 8:38-50, 2010 • doi: 10.5049/EBP.2010.8.1.38    43
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contrast, low plasma aldosterone level and renin activity 
represent pseudohyperaldosteronism. Based on the plasma 
cortisol concentration, three subgroups can be readily 
divided. Patients with high plasma cortisol concentrations 
may have ectopic adrenocorticotrophic hormone (ACTH), 
Cushing’s syndrome or exogenous hydrocortisone 
administration. Low plasma cortisol concentration suggests 
the diagnosis of congenital adrenal hyperplasia (CAH) due 
to either 11β-hydroxylase or 17α-hydroxylase deficiencies 
(11β-OHD and 17α-OHD). A normal plasma cortisol level 
can be found in 11-deoxycorticosterone (DOC) producing 
adenoma, Liddle’s syndrome, apparent mineralocorticoid 
excess, and chronic licorice ingestion. 
a. Genetic hypokalemia associated with mineralocorticoid 
excess state
The mineralocorticoid receptor (MR), the major regula-
tor of ENaC activity, is normally activated by aldosterone. 
Genetic mutations causing abnormalities in aldosterone 
secretion or production of other steroids that activate the 
MR will lead to hypertension and hypokalemia
24). 
i. Glucorticoid-remediable aldosteronism
GRA is an autosomal dominant form of hypertension 
caused by a chimeric gene duplication arising from 
unequal crossing over between two closely related genes 
involved in adrenal steroid biosynthesis
25). These two genes 
are 11β-hydroxylase (CYP11B1) encoding aldosterone 
synthase for aldosterone biosynthesis in the adrenal 
glomerulosa regulated by angiotensin II and aldosterone 
synthase (CYP11B2) encoding 11β-hydroxylase for 
cortisol biosynthesis in the adrenal fasciculata regulated 
by ACTH. The unequal crossover between CYP11B1 and 
CYP11B2 genes results in CYP11B2 that allows aldosterone 
synthesis to be under the control of regulatory promoter 
sequences of CYP11B1 by ACTH rather than its normal 
regulator, angiotensin II. Aldosterone secretion thus 
becomes linked to cortisol secretion, leading to clinical and 
Fig. 2. Algorithm for the approach to hypokalemia with a high urine [K
+]CCD (TTKG). CCD, cortical collecting duct; TTKG, transtubular K
+ 
gradient; ECF, extracellular fluid; BP, blood pressure; RVH, right ventricular hypertrophy; AME, Apparent mineralocorticoid excess; DOC, 
11-deoxycorticosterone; ACTH, adrenocorticotrophic hormone; RTA, renal tubular acidosis; GS, Gitelman’s syndrome; BS, Bartter’s 
syndrome
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laboratory features of primary aldosteronism. Exogenous 
glucocorticoids diminish the ACTH-regulated chimeric 
genes, in turn suppressing the secretion of aldosterone, 
leading to reversal of the features of GRA.
ii. CAH due to 11β-OHD and 17α-OHD
Two forms of CAH have hypertension and hypokalemia 
accompanying a characteristic phenotype with abnormal 
androgen production and sexual differentiation
26). They 
are 11β-OHD and 17α-OHD caused by CYP11B1 and 
CYP17 mutations, respectively. Increased ACTH levels in 
11β-OHD leads to elevation of 11-deoxycortisol (compound 
S) and DOC, causing MES. Cortisol precursors are 
diverted through the 17,20-lyase pathway and this results 
in hyperandrogenemia, causing acne, hyperpigmentation, 
and an enlarged phallus in males and prenatal virilization 
of genitalia in the female newborn
27). 17α-OHD has both 
defective 17α-hydroxylase and 17,20-lyase activities of 
the 17α-hydroxylase essential for the synthesis of cortisol 
and gonadal hormones. Lack of 17,20-lyase activity in 
17α-OHD prevents androgen synthesis and results in under-
virilization in males and failure of spontaneous pubertal 
development in females. Steroid therapy ameliorates the 
hypertension and hypokalemia as well as the associated 
signs and symptoms.
iii. Liddle’s syndrome
It is characterized by autosomal dominant transmission 
of early onset hypertension associated with hypokalemia, 
metabolic alkalosis, suppressed plasma renin activity, and 
extremely low plasma aldosterone levels
28). This disease 
is caused by mutations in either the β or the γ subunit of 
ENaC that delete or alter their cytoplasmic C termini. 
The mutated ENaC are not internalized (clathrin-coated 
pits pathway) or degraded (Nedd4 pathway), and instead 
remain in an activated form on the cell surface. The 
channel is amiloride and triamterene sensitive provided 
their concentrations are high enough in luminal fluid, 
explaining the efficacy of these K
+-sparing diuretics in the 
syndrome.
iv. Apparent mineralocorticoid excess (AME)
AME is a rare but potentially fatal autosomal re-
cessive form of hypertension and hypokalemic me-
tabolic alkalosis associated with hyporeninemia and 
hypoaldosteronemia and an abnormal ratio of urinary 
metabolites of cortisol with a high tetrahydrocortisol:tet
rahydrocortisone (THF:THE) ratio
29). AME is caused by 
mutations in the gene (HSD11B2) encoding renal-specific 
11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2). 
11β-HSD2 is responsible for converting cortisol to 
cortisone in the principal cells of distal tubules and crucial 
for protecting the MR from being occupied by cortisol. 
The hallmark features in AME resemble those in licorice 
ingestion because licorice contains glycyrrhetinic acid, 
which inhibits 11β-HSD2
30).  
(2) Slow Cl¯ disorders
Because Cl¯ reabsorption in the CCD is diminished, ECF 
volume is usually contracted and thus BP is relatively low to 
normal. Because extracellular K
+ loss is often accompanied 
by ECF HCO3¯ or Cl¯ loss, slow Cl¯ disorders can have 
either hyperchloremic metabolic acidosis or hypochloremic 
metabolic alkalosis.  
a. Hypochloremic metabolic alkalosis
Metabolic alkalosis is diagnostically useful in patients 
with severe KCl depletion. An assessment of urine Na
+ 
and Cl¯ may reveal the basis for renal tubular electrolyte 
disorders and distinguish it from non-renal Na
+ loss 
(Fig. 2). Low excretion of Na
+ and Cl¯ indicate remote 
vomiting, remote or yesterday’s diuretics, Cl¯-losing 
diarrhea (e.g. congenital chloridorrhea), or excessive 
sweating. Low urine Na,
+ but high Cl¯ excretion, in the 
presence of hypokalemia and metabolic alkalosis suggests 
laxative abuse or some chronic diarrhea states with chronic 
stimulation of renal NH4
+ excretion. Conditions of high 
Na
+ excretion, but low Cl¯, suggests the presence of an 
anion that is not reabsorbed. If the urine is alkaline (pH 
>7), vomiting and/or ingestion of bases are the likely 
causes. If the urine is not alkaline, intake or generation Electrolyte Blood Press 8:38-50, 2010 • doi: 10.5049/EBP.2010.8.1.38    45
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of anions that are poorly reabsorbed by the kidney is 
likely
31). A high urine Na
+ and Cl¯ excretion is indicative 
of the recent use of diuretics, intrinsic renal disease, or 
lack of signaling to stimulate NaCl reabsorption. Inherited 
or acquired renal tubular disorders such as Gitelman’s 
syndrome (GS), Bartter’s syndrome (BS), and related drug-
induced toxic disorders, such as from aminoglycosides, 
cisplatin, diuretics, and foscarnet, are often the diagnoses
32). 
The evaluation of urine divalent Mg
2+ and Ca
2+ excretion 
helps localize the exact tubular defect. High urine Ca
2+ 
and Mg
2+ excretion is universally present in lesions of the 
loop of Henle (LOH) whereas low urine Ca
2+ and high 
Mg
2+ excretion is invariably found in lesions of the DCT
33). 
i. Bartter’s syndrome (BS) and Gitelman’s syndrome (GS)
BS and GS are autosomal recessive renal tubular disor-
Table 1. Genetic Mutations in Inherited Hypokalemia
Disease Inheritance Cell/organ OMIM Mutated gene Channels/proteins
Increased K
+ shift FPP, type I/II AD Skeletal muscle 170400 CACNA1S/SCN4A Dihydropyridin-sensitive voltage 
gated Ca
2+ channel/ tetrodotoxin-
sensitive Na
+ channel
Andersen’s syndrome AD Skeletal muscle, heart 600681 KCNJ2 Kir2.1 channel 
Gastrointestinal K
+ 
loss
CLD AR Colon, ileum 214700 DRA Cl¯/OH¯(HCO3¯) exchanger
Sweat K
+ loss CF AR Sweat gland 602421 CFTR Chloride channel
Renal K
+ loss with 
MES
GRA AD Adrenal glands 103900 Chimeric 
CYP11B1/CYP11B2
11β-hydroxylase/aldosterone 
synthase
CAH AR Adrenal glands 202010/202110 CYP11B1/CYP17 11β-hydroxylase/17α-hydroxylase
Liddle’s syndrome AD CD, kidney 177200 SCNN1B/SCNN1G β or γ subunit of epithelial Na
+ 
channel
AME AR CD, kidney 207765 HSD11B2 11β-hydroxysteroid dehydrogenase 
type 2
Renal K
+ loss with 
normotension and 
metabolic alkalosis
BS, type I AR LOH 601678 SLC12A1 Na
+/K
+/2Cl¯ cotransporter
BS, type II AR LOH 241200 KCNJ1 ROMK channel
BS, type III AR LOH, DCT 607364 CLCNKB Kidney-specific basolateral Cl¯ 
channel
BS, type IV AR LOH/inner ear 602522 BSND Barttin
BS, type V AR LOH/parathyroid 601199 CASR Calcium-sensing receptor
GS AR DCT 263800 SLC12A3 Thiazide-sensitive Na
+/Cl¯ 
cotransporter
SeSAME syndrome AR DCT/brain/inner ear 612780 KCNJ10 Kir4.1 channel 
Renal K
++ loss with 
normotension and 
metabolic acidosis
pRTA with ocular lesion AR PCT, eye 604278 SLC4A4 Basolateral Na
+/
HCO3¯cotransporter
dRTA with deafness AR CD, inner ear 267300 ATP6V1B1/
ATP6V0A4
Apical H
+-ATPase of α-intercalated 
cells
dRTA with/without 
anemia
AR CD, RBC 602722 SLC4A1 Basolateral HCO3¯/Cl¯exchanger
Combined pRTA and 
dRTA
AR PCT, CD, bone 259730 CAII Carbonic anhydrase II
PCT,  proximal convoluted tubule; LOH, loop of Henle; DCT, distal convoluted tubule; CD, collecting duct; AD, autosomal dominant; AR, autosomal r ecessive; 
RBC, red blood cell; GRA, glucocorticoid-remediable aldosteronism; FPP, familial periodic paralysis; CLD, congenital chloride-losing diarrhea; CF, cystic fibrosis; 
CAH, congenital adrenal hyperplasia; AME, apparent mineralocorticoid excess; BS, Bartter’s syndrome; GS, Gitelman’s syndrome; pRTA, proximal renal tubular 
acidosis; dRTA, distal renal tubular acidosis; MES, mineralocorticoid excess state; SeSAME, seizures, sensorineural deafness, ataxia, mental retardation, and 
electrolyte imbalance.46      SH Lin et al.  •  A Practical Approach to Genetic Hypokalemia
Copyright © 2010 The Korean Society of Electrolyte Metabolism
ders characterized by chronic hypokalemia with renal 
K
+ wasting, metabolic alkalosis, renal salt wasting with 
low to normal BP and secondary  hyperreninemia and 
hyperaldosteronism. BS results from defective reabsorption 
of NaCl in the LOH whereas GS is secondary to defective 
reabsorption of NaCl in the DCT. At the molecular 
level, GS is mostly due to inactivating mutations in the 
SLC12A3 gene, which encodes the thiazide-sensitive Na
+/
Cl¯ cotransporter (NCC) on the apical membrane of the 
DCT
34). The five subtypes of BS arise from inactivation 
mutations in genes encoding the Na
+/K
+/2Cl¯ cotransporter 
(NKCC2), K
+ channel (ROMK), kidney-specific Cl¯ 
channel (CLCNKB), barttin (BSND) and calcium-sensing 
receptors (CaSR)
35,  36) (Table 1, Fig. 3). Recently, a complex 
syndrome consisting of a combination of epilepsy, ataxia, 
sensorineural deafness and renal tubulopathy featuring 
laboratory findings of GS (EAST or SeSAME syndrome) 
has been described, due to inactivating mutations in the 
gene encoding Kir4.1, which is also highly expressed in 
the basolateral membrane of the DCT
37, 38). Loss of Kir4.1 
function may reduce Na
+,K
+-ATPase and accumulate 
intracellular Na
+, leading to reduced salt reabsorption in 
the DCT, similar to GS.                         
A maternal history of polyhydramnios, age of onset, 
neurologic symptoms, deafness, presence of nephrocalcinosis 
or renal stones, and serum divalent concentration with their 
urine excretion rates help distinguish among the subtypes 
of BS and GS. Because Cl
- channels are expressed in 
both the basolateral membrane of LOH and DCT, some 
patients with classical BS may have clinical profiles similar 
to that of GS. Unlike BS, non-steroid anti-inflammatory 
drugs (NSAIDs) are usually not effective in patients with 
GS due to the relatively normal urinary prostaglandin E2 
excretion. 
The degree of chronic hypokalemia has been reported 
to be milder in GS than BS. In fact, profound hypokalemia 
is not uncommon in patients with GS and is also difficult 
to correct even with high K
+ supplementation and the use 
of K
+-sparing agents. Besides ROMK channels,  Ca
2+-
activated maxi-K
+ channels (BKCa), a large-conductance 
channel stimulated by increased distal renal tubule flow, 
play an important role in K
+ secretion when the flow rate 
Fig. 3. Transport proteins in the thick ascending limb (TAL) of loop of Henle (LOH) (left panel) and distal convoluted tubule 
(DCT) (right panel) affected by gene mutations. Mutations that inactivate Na
+/K
+/2Cl¯ cotransporter (NKCC2) or renal outer 
medullary K
+ channel (ROMK) lead to antenatal Bartter syndrome/hyperprostaglandin E syndrome (aBS/HPS) (BS type I and 
II) and mutations inactivating ClCKb cause classic Bartter syndrome (cBS) (BS type III). Mutations in barttin (chloride channel 
βsubunit) cause antenatal BS with sensorineural deafness (BSND) (BS type IV). Mutations that activate the calcium-sensing 
receptors (CaSR) occur in patients with autosomal dominant hypoparathyroidism (ADH) (BS type V). Mutations inactivating 
Na
+/Clˉ cotransporter (NCC) or basolateral Clˉ channel (ClC-Kb) can cause Gitelman's syndrome (GS). Mutations in Kir4.1 
channel cause seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME) 
syndrome. ADH, anti-diuretic hormoneElectrolyte Blood Press 8:38-50, 2010 • doi: 10.5049/EBP.2010.8.1.38    47
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to the CCD is increased
39). The importance of maxi-K
+ 
channels in renal K
+ secretion is further supported by the 
finding that BS patients with ROMK mutations do not 
have hyperkalemia but hypokalemia. Mutations of ROMK 
decrease NaCl and flow reabsorption in the LOH and 
result in increased distal flow delivery to the CCD where 
flow-stimulated K
+ secretion via maxi-K
+ channels are 
enhanced despite the loss of functional ROMK
40). We have 
found that  both ROMK1 and maxi-K
+ expression were 
increased in the distal renal tubules of GS-causing knockin 
mice on normal K
+ diet, suggesting that both channels are 
involved in renal K
+ wasting in GS (unpublished data). The 
mice on a high K
+ diet still had hypokalemia, indicating 
that increased intake was matched by increased excretion. 
Although ROMK1 expression was unchanged between 
normal and high K
+ diets, maxi-K
+ was further increased, 
suggesting that ROMK1 expression had reached a ceiling, 
but not maxi-K
+ expression, which may also be stimulated 
by K
+ repletion and aldosterone. Over-expression/
activation of maxi-K
+ may be responsible for the persistent 
hypokalemia in GS patients despite K
+ supplementation 
(Fig. 4). These findings raise the possibility of maxi-K
+ 
inhibitors as an alternate therapeutic target in managing 
chronic refractory hypokalemia.
b. Hyperchloremic metabolic acidosis
Hyperchloremic metabolic acidosis provides an im-
portant diagnostic clue for the presence of a patho-
physiologic process involving both K
+ depletion and direct 
or indirect loss of HCO3¯. Estimating the urine NH4
+ 
concentration unveils the basis of metabolic acidosis 
associated with K
+ depletion
41). The excretion of NH4
+ is 
low in patients with renal tubular acidosis (RTA), whereas, 
this excretion is not depressed in simple gastrointestinal 
loss of NaHCO3. An indirect estimate of NH4
+ can be 
obtained from the urine anion gap (Na
++K
+–Cl¯) or 
osmolal gap (measured-calculated urine osmolality)/2. The 
causes for patients who do not have a low NH4
+ excretion 
rate include gastrointestinal loss of HCO3¯, chronic toluene 
abuse, treatment of diabetic acidosis with insulin, and 
ureteral diversion. Positive urine net charge and osmolal 
gap less than 100 mOsm/kg H2O are indicative of low 
urine NH4
+ excretion, pointing to the diagnosis of RTA. 
RTA can be proximal or distal in origin. Intravenous 
NaHCO3 loading at a rate of 2-3 mEq/kg/hour can be 
administered to separate proximal from distal RTA. 
Fig. 4. Mechanisms for persistent hypokalemia in Gitelman's syndrome (GS). Enhanced epithelial 
Na
+ channels (ENaC), renal outer medullary K
+ channel (ROMK)1 and Maxi-K expression leads 
to hypokalemia (middle). High K
+ supplement stimulates more accentuated maxi-K expression, 
accounting for persistent hypokalemia (left). DCT, distal convoluted tubule; CNT, cortical 
connecting tubules; CCD, cortical colleting duct.48      SH Lin et al.  •  A Practical Approach to Genetic Hypokalemia
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i. Inherited isolated proximal RTA
Most of the filtered HCO3¯ is reabsorbed in the proximal 
convoluted tubules (PCT) as a result of H
+ secretion via 
the electroneutral Na
+/H
+ exchanger 3 (NHE3) in the 
luminal membrane and HCO3¯ exit via the electrogenic 
Na
+/HCO3¯ cotransporter (NBC1) in the basolateral 
membrane. Defects in NHE3 or NBC1 can theoretically 
reduce the reabsorption of filtered HCO3¯ and cause 
proximal RTA (pRTA). Mutations in the NHE3 gene have 
not been identified in patients with proximal RTA to date. 
On the other hand, mutations in the NBC1 gene (SLC4A4) 
have been reported in patients with autosomal recessive 
isolated proximal RTA
42). Because NBC1 is also expressed 
in the ocular tissues and brain, patients with inactivating 
mutations in NBC1 have ocular abnormalities (glaucoma, 
band keratopathy, and cataracts) as well as calcifications of 
the basal ganglia. Of note, hypokalemia is almost always 
present and can be very severe when a high dose of oral 
NaHCO3 is given. 
ii. Inherited distal RTA
Apical H
+-ATPase pump and basolateral Cl¯/HCO3¯ 
exchanger (anion exchanger 1, AE1) in the late distal 
tubule (predominantly in α-intercalated cells) participate 
in the excretion of NH4
+, which adds new HCO3¯ to the 
body. Genes encoding two H
+-ATPase subunits specific 
to intercalated cells have been identified as ATP6V1B1 
and ATP6V0A
43). Because ATP6V1B1 is also expressed in 
endolymphatic sac epithelia, mutations in ATP6V1B1 cause 
distal RTA with sensorineural hearing loss, whereas, distal 
RTA with preserved hearing is caused by mutations in 
ATP6V0A4. AE1 (SLC4A1) is also present in erythrocytes 
and inactivating mutation in AE1 causes distal RTA and 
possible anemia
44). Hypokalemia in hereditary distal RTA is 
often severe. First, low distal H
+ secretion reduces luminal 
HCO3¯ reabsorption and this leads to bicarbonaturia. 
Second, the mistargeting of AE1 due to the second 
mutation in AE1 leads to HCO3 secretion. Reminiscent of 
alkalinized intercalated cells in Sjogren’s syndrome with 
distal RTA, high luminal HCO3¯ may lead to augmented 
K
+ secretion and hypokalemia. 
iii. Inherited proximal and distal RTA
Carbonic anhydrase II (CAII) is known to be expressed 
in both proximal and distal nephron segments and 
participates in H
+ secretion in both the proximal and distal 
nephron; CAII is also expressed in brain and osteoclasts. 
Mutations in CAII can lead to an autosomal recessive 
proximal and distal RTA with osteopetrosis and cerebral 
calcification
45). The bone thinning effect of the coexistent 
metabolic acidosis in CAII deficiency may protect the 
osteopetrotic bones from the excessive thickening 
generated by osteoclast dysfunction. 
Therapeutic strategy in genetic hypokalemia
Genetically engineered mice are often used as animal 
models of human diseases and are vital tools in investigating 
molecular pathogenesis of disease and developing and 
testing novel therapies. It is worthy to emphasize that 
knock-out mice typically represent null mutations and 
could be used to study only the effects of the loss of a 
gene, not a specific mutation
46). Knockin strategies, where 
homologous recombination in embryonic stem (ES) cells is 
used to replace the endogenous gene with a mutant variant 
without any other disruption of the gene, can be used to 
address the effects of specific sequence changes on gene 
and protein function
47). Therefore, knockin mice accurately 
represent human diseases caused by specific mutations, 
such as missense, nonsense, or deletion mutations. More 
importantly, mutation-specific approaches according 
to the different classes of mutations are currently under 
investigation to provide a new alternative therapy in 
genetic disorders. We believe that the application of these 
diseases-causing knock-in mice may address more specific 
questions regarding the pathogenesis and new directions 
in rescue therapies; for instance, rational application of 
aminoglycosides or premature termination codon (PTC) 
124 for nonsense mutations and pharmacologic chaperones 
for missense mutations
48). Electrolyte Blood Press 8:38-50, 2010 • doi: 10.5049/EBP.2010.8.1.38    49
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Conclusion
Apart from a detailed history and careful physical 
examination, the measurement of urine K
+ excretion rate 
by spot and/or 24 hour urine, and assessment of blood acid-
base status helps discriminate the causes of hypokalemia. 
Once the clinical diagnosis suggests a likely molecular basis 
for the disorder, genetic analysis may prove the diagnosis. 
Genetic causes of hypokalemia are shown in Table 1. 
Creation and investigation of disease-causing knockin mice 
as a model of genetic hypokalemia will not only provide a 
much better understanding of the underlying mechanisms; 
but also set the stage for the development of novel therapies 
in the future. 
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